SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): July 14, 2000
MIRAVANT MEDICAL TECHNOLOGIES
(Exact name of Registrant as specified in its charter)
Delaware 0-2554 77-0222872
(State or other jurisdiction of Commission File Number) (I.R.S. Employer
incorporation or organization) Identification Number)
336 Bollay Drive
Santa Barbara, CA 93117
(Address of principal executive offices)
(805) 685-9880
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. OTHER EVENTS
On July 14, 2000, Miravant Medical Technologies issued a press release
announcing that the Board of Directors of Miravant Medical Technologies approved
the adoption of a Preferred Stock Rights Agreement. The press release is
attached as Exhibit 99 to this Form 8-K.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
Exhibit 99 Miravant Medical Technologies Press Release issued
July 14, 2000.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act or 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Miravant Medical Technologies
(Registrant)
Date: July 14, 2000
By: /s/ John M. Philpott
-------------------------
Name: John M. Philpott
Title: Chief Financial Officer
<PAGE>
EXHIBIT INDEX
Exhibit
Number
99 Miravant Medical Technologies Press Release issued July 14, 2000.
